U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07459634) titled 'A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC' on March 05.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Study Start Date: April 25
Study Type: INTERVENTIONAL
Condition:
Extensive-stage Small-cell Lung Cancer
Intervention:
DRUG: Lurbinectedin
Administered by intravenous (IV) infusion
DRUG: Durvalumab
Administered by intravenou...